1、除已披露事项外,本人不存在其他与上市公司有关的应披露而未披露的 重大信息,包括但不限于重大资产重组、股份发行、收购、债务重组、业务重组、 资产剥离、资产注入、股份回购、股权激励、破产重整、重大业务合作、引进战 略投资者等重大事项。 2、本人在上市公司本次股票交易异常波动期间,不存在买卖上市公司股票 的情况。 特此函复。 蓝波: P 舒畅: 2024年 11月 4日 《关于健之佳医药连锁集团股份有限公司股票交易异常波动的问询 函》之回函 健之佳医药连锁集团股份有限公司: 贵公司《关于健之佳医药连锁集团股份有限公司股票交易异常波动问询函》 已悉收,本人作为健之佳医药连锁集团股份有限公司(以下简称"上市公司") 实际控制人,经认真自查,现回复如下: ...

Investment Rating - The report maintains a "Buy" rating for the company [2][5]. Core Views - The company's revenue growth has slowed due to a challenging consumption and policy environment, leading to significant pressure on profits. However, a recovery is expected in 2025 as the company adjusts its product categories and controls costs [2][3]. Financial Summary - For the first three quarters of 2024, the company achieved revenue of 6.735 billion yuan, a year-on-year increase of 3.6%, while net profit attributable to shareholders was 101 million yuan, down 63.8%. In Q3 2024, revenue was 2.25 billion yuan, up 4.08%, with net profit of 38 million yuan, down 68.46% [3][4]. - The company has adjusted its earnings per share (EPS) forecasts for 2024-2026 to 1.14, 1.70, and 1.98 yuan, respectively, down from previous estimates of 2.92, 3.54, and 4.22 yuan [3]. - The target price has been revised down to 28.90 yuan, reflecting a price-to-earnings (PE) ratio of 17 times for 2025 [3][5]. Revenue and Profitability - Revenue growth has been impacted by several factors, including a decline in medical insurance settlement income, high proportions of new stores with lower output, and a challenging consumption environment affecting traditional Chinese medicine and health food products [3]. - The company has seen an increase in non-drug revenue, primarily due to the introduction of high-margin skincare products [3]. Store Operations - As of Q3 2024, the total number of stores reached 5,501, with 75 new openings and 18 closures. The company is focusing on improving store operational quality amid a competitive market [3]. Cost Management - The company is experiencing increased expense ratios due to fixed costs associated with store operations. In Q3 2024, the sales, management, and financial expense ratios increased year-on-year [3]. - The company plans to enhance its own brand product development and control costs to mitigate the decline in gross margins [3]. Future Outlook - The company is expected to benefit from improvements in the consumption and policy environment, as well as the further clearing out of small pharmacies, leading to a potential recovery in performance in 2025 [3].

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 30.3 yuan, compared to the current price of 23.31 yuan [1]. Core Views - The company's revenue for the first three quarters of 2024 reached 6.74 billion yuan, with a year-on-year increase of 3.6%. However, the net profit attributable to the parent company and the net profit after deducting non-recurring gains and losses saw significant declines of 63.8% and 64.3% respectively, primarily due to the ongoing implementation of medical reform policies [1][2]. - The company has been adjusting its operational strategies to mitigate the impact of policy changes, focusing on enhancing non-medical insurance revenue through differentiated competition and professional services [2]. - Store expansion has slowed down, with a net increase of 385 stores in the first nine months of 2024, bringing the total to 5,501 stores, a 7.5% increase from the beginning of the year [2]. - The gross profit margin has come under pressure, with a decline of 1.2 percentage points to 36.8% in Q3 2024, while the net profit margin decreased by 3.9 percentage points to 1.7% [2]. Financial Summary - The company forecasts net profits attributable to the parent company for 2024-2026 to be 210 million, 237 million, and 268 million yuan, reflecting a year-on-year change of -49%, +13%, and +13% respectively [2][3]. - The projected revenue for 2024 is 9.35 billion yuan, with a growth rate of 3.0%, and is expected to reach 10.28 billion yuan in 2025, growing by 10.0% [3]. - The company's total assets are projected to increase from 9.949 billion yuan in 2023 to 11.304 billion yuan in 2024 [6].

Investment Rating - The report does not specify a clear investment rating for the company [1]. Core Insights - The company has shown steady growth in its traditional Chinese and Western medicine business, with a revenue increase of 4.3% in the first nine months of 2024, accounting for 76.8% of total sales [1][2]. - The company reported a total revenue of 6.74 billion yuan for the first three quarters of 2024, reflecting a 3.6% year-on-year increase, while the net profit attributable to shareholders decreased by 63.8% to 100 million yuan [2][4]. - The company is expanding its store network through a combination of self-built and acquired stores, with a total of 5,501 stores as of Q3 2024, representing a 7.5% increase from the beginning of the year [2][3]. Summary by Sections Financial Performance - For Q3 2024, the company achieved a revenue of 2.25 billion yuan, up 4.1% year-on-year, but the net profit attributable to shareholders fell by 68.5% to 40 million yuan [2]. - The projected net profits for 2024-2026 are estimated at 250 million yuan, 310 million yuan, and 360 million yuan respectively [1][4]. Business Expansion - The company is focusing on increasing the number and scale of stores in county-level and above markets, with 94.8% of its retail stores located in these areas [3]. - The company has a strategic plan to penetrate deeper into the market, particularly in cities with significant growth potential, while maintaining a strong presence in provincial capitals [3]. Revenue and Profitability Forecast - The company anticipates a revenue growth rate of 3% for retail business in 2024, with a projected compound annual growth rate of 30% for its professional services to pharmaceutical and convenience suppliers [6]. - The overall revenue forecast for 2024-2026 is expected to grow from 8.39 billion yuan in 2024 to 10.71 billion yuan in 2026, with a corresponding increase in gross margin [6][8].

证券代码：605266 证券简称：健之佳 公告编号：2024-099 健之佳医药连锁集团股份有限公司 健之佳医药连锁集团股份有限公司（以下简称"公司"） 于 2024 年 9 月 19 日召开第六届董事会第七次会议审议通过了《关于回购公司股份的方案》，同意公 司使用自有资金通过集中竞价交易方式回购公司部分股份，所回购股份将在披露 回购结果暨股份变动公告 12 个月后根据相关规则择机采用集中竞价交易方式出售。 本次回购金额不低于人民币 2,000 万元且不超过人民币 3,000 万元（均含本数）， 回购股份价格不超过人民币 29.80 元/股（含）。本次回购实施期限为自公司董事 会审议通过本次回购方案之日起不超过 3 个月。具体内容详见公司在上海证券交 易所网站（www.sse.com.cn）披露的《关于以集中竞价交易方式回购股份方案暨 回购报告书》（公告编号：2024-080）。 二、 回购股份的进展情况 根据《上市公司股份回购规则》、《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，在回购股份期间，上市公司应当每个月的前三个 交易日内，公告截至上月末的回购进展情况。现公司将截至 202 ...

证券代码：605266 证券简称：健之佳 公告编号：2024-098 健之佳医药连锁集团股份有限公司 关于回购股份事项前十大股东及前十大无限售条件股东 持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、前十名股东持股情况 1 | 7 | 国泰基金管理有限公司－社保基金四二一 | 2,454,276 | 1.57 | | --- | --- | --- | --- | | | 组合 | | | | 8 | 中国建设银行股份有限公司－国泰大健康 | 2,218,272 | 1.42 | | | 股票型证券投资基金 | | | | 9 | 健之佳医药连锁集团股份有限公司－2024 | 2,051,152 | 1.31 | | | 年员工持股计划 | | | | 10 | 兴业银行股份有限公司－融通鑫新成长混 | 1,998,989 | 1.28 | | | 合型证券投资基金 | | | 注：以上股东的持股数量为合并普通账户和融资融券信用账户后的持股数量 总数。 | 序号 | 股东名称 | 持有数量 | 占公司无限 ...

关于 2024 年第三季度业绩说明会召开情况汇总 2024 年 10 月 30 日（星期三）上午 09:00-10:00，健之佳医药连锁集团 股份有限公司（以下简称"公司"）通过上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/）网络互动召开了 2024 年第三季度业绩说明 会，现将活动情况公告如下： 本次业绩说明会中投资者提出的问题及回复整理如下： 一、 请问贵公司是否考虑增持维护广大股东的利益？ 尊敬的投资者您好，感谢您对公司的关注。 公司重视股东的回报，坚持"稳定的收益、资产的增值是对股东的回报" 这一理念，长期专注核心主业，以合规经营、专业服务、业务转型应对市场、 政策、经营方面导致的行业重大变化。 业务合规安全基础上的稳健发展，是维护股东利益的长期基础和根本，以 此为基础应对资本市场、公司市值的波动。 公司建立了通过分红、回购等方式与股东分享经营成果、维护公司价值及 股东权益的规范机制。2024 年 6 月，公司员工持股计划以集中竞价交易方式 增持公司股份 5,000 万元。 2020 年 12 月公司上市后，3 个年度均通过较高比例现金分红维护股东利 益； ...

●回购股份的目的：维护公司价值及股东权益 ● 回购股份用途：本次回购的股份将按规范要求择机采用集中竞价交易方式 出售，并在披露回购结果暨股份变动公告后 3 年内完成出售。 ● 回购股份价格：不超过 31.69 元/股（含），该回购价格上限未超过董事 会审议通过本次回购股份方案决议前 30 个交易日公司股票交易均价的 150%。 证券代码：605266 证券简称：健之佳 公告编号：2024-096 健之佳医药连锁集团股份有限公司 关于以集中竞价方式回购股份的预案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份方式：以集中竞价交易方式进行股份回购。 ● 回购股份期限：自董事会审议通过回购股份方案之日起不超过 3 个月。 ● 相关股东是否存在减持计划：经问询，截至董事会审议本次回购方案决议 之日，公司持股董监高、控股股东、实际控制人、回购提议人、持股 5%以上股东 在未来 3 个月、未来 6 个月暂无减持公司股份的计划。 若相关人员未来拟实施减持股份计划，将严格遵守相关法律法规的规定，履 行信息披露 ...

北京德恒（昆明）律师事务所 关于健之佳医药连锁集团股份有限公司 终止实施 2024 年限制性股票激励计划暨 回购注销限制性股票相关事项的 关于健之佳医药连锁集团股份有限公司终止实施 2024 年 北京德恒（昆明）律师事务所 限制性股票激励计划暨回购注销限制性股票相关事项的法律意见 释 义 法律意见 云南省昆明市西山区西园路 126 号"融城优郡"B5 幢 3-4 层 电话:0871-63172192 传真: 0871-63172192 邮编: 650032 | 释 义 | 1 | | --- | --- | | 正 文 | 1 | | 一、本次激励计划的实施情况 | 1 | | 二、本次终止及回购注销的批准与授权 | 2 | | 三、本次终止及回购注销的基本情况 | 2 | | 四、结论意见 | 3 | 本法律意见中，除非文中另有所指，下列简称具有如下特定含义： | 健之佳、公司 | 指 | 健之佳医药连锁集团股份有限公司 | | --- | --- | --- | | 本次激励计划 | 指 | 健之佳医药连锁集团股份有限公司2024年限 | | | | 制性股票激励计划 | | 本次终止及回购注销 | 指 ...

证券代码：605266 证券简称：健之佳 公告编号：2024-092 健之佳医药连锁集团股份有限公司 第六届监事会第六次会议决议公告 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的 《2024 年第三季度报告》。 2、审议《关于公司对外投资设立职业技能培训学校的议案》 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 健之佳医药连锁集团股份有限公司（以下简称"公司"）第六届监事会第六 次会议通知于 2024 年 10 月 24 日以电子邮件方式通知全体监事，会议于 2024 年 10 月 29 日上午 10：30 以现场方式在云南省昆明市盘龙区联盟街道旗营街 10 号 健之佳总部 18 楼召开，应参加监事 3 人，实际参加监事 3 人，会议由监事会主 席金玉梅女士主持，符合《公司法》及《公司章程》等有关规定。 二、监事会会议审议情况 全体与会监事经认真审议和表决，形成以下决议： 1、审议《关于公司<2024 年第三季度报告>的议案》 议案表决情况：同意 3 票；反对 0 票 ...